Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EPS (Basic): 2022-2025

Historic EPS (Basic) for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$0.65.

  • Stoke Therapeutics' EPS (Basic) fell 38.30% to -$0.65 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.73, marking a year-over-year increase of 134.76%. This contributed to the annual value of -$1.65 for FY2024, which is 30.67% up from last year.
  • As of Q3 2025, Stoke Therapeutics' EPS (Basic) stood at -$0.65, which was down 62.50% from -$0.40 recorded in Q2 2025.
  • Stoke Therapeutics' EPS (Basic)'s 5-year high stood at $1.95 during Q1 2025, with a 5-year trough of -$0.69 in Q2 2023.
  • Over the past 3 years, Stoke Therapeutics' median EPS (Basic) value was -$0.53 (recorded in 2023), while the average stood at -$0.29.
  • The largest annual percentage gain for Stoke Therapeutics' EPS (Basic) in the last 5 years was 442.11% (2025), contrasted with its biggest fall of 38.30% (2025).
  • Quarterly analysis of 4 years shows Stoke Therapeutics' EPS (Basic) stood at -$0.65 in 2022, then rose by 7.69% to -$0.60 in 2023, then surged by 71.67% to -$0.17 in 2024, then tumbled by 38.30% to -$0.65 in 2025.
  • Its EPS (Basic) was -$0.65 in Q3 2025, compared to -$0.40 in Q2 2025 and $1.95 in Q1 2025.